Kingsley L. Taft

Kingsley L. Taft

Partner Co-Chair, Life Sciences Practice
Kingsley L. Taft

Kingsley Taft is a senior partner and national co-chair of Goodwin's Life Sciences Practice and member of the Allocations Committee. He represents emerging to mature life sciences companies in all aspects of their business and legal affairs, including company formation, venture financings, strategic alliances, M&A, IPOs and other financing and commercial transactions. Mr. Taft has extensive experience in assisting clients with JVs, strategic alliances, licenses and collaborations.

Mr. Taft has been recognized as a leading life sciences attorney by numerous legal guides. He has been annually ranked for more than a decade in Chambers USA: America’s Leading Lawyers for Business (Nationwide, Life Sciences: Corporate/Commercial – Band 1). Mr. Taft was inducted into the LMG Life Sciences Hall of Fame, an honor recognizing only a handful of attorneys for their industry contributions.

Before attending Harvard Law School, Mr. Taft earned a B.S in Chemistry from Yale University and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.

Mr. Taft regularly serves as outside general counsel to biotechnology, pharmaceutical, medical device and medtech companies, closely advising management and directors as these companies raise capital, in-license and acquire IP and other assets, and then partner their technology, all with a view towards growth and liquidity.




Representative Matters

Repräsentative Angelegenheiten


Strategic Alliances and M&A
  • Delinia Therapeutics in its sale to Celgene, valued up to $775 million with up-front payment of $300 million
  • Royalty Pharma in its acquisition from Perrigo Company of royalty rights to Tysabri, for up to $2.8 billion
  • Pieris Pharmaceuticals in its collaboration with Servier for a dual-checkpoint inhibitor and up to seven other immuno-oncology bispecific drug candidates, for a deal value of up to €1.7 billion
  • Teva Pharmaceuticals in its global agreement with Regeneron for the phase 3 novel nerve growth factor antibody fasinumab, for $250 million upfront and a share in its global commercial value
  • Moderna Therapeutics in numerous strategic transactions with AstraZeneca, Alexion and Merck with aggregate upfront deal value of more than $650 million; most recently, in its strategic collaboration with Merck for mRNA-based personalized cancer vaccines, with an upfront payment of $200 million
  • Morgan Stanley as financial advisor to Stemcentrx in its sale to AbbVie for $5.8 billion in cash and stock, and up to an additional $4 billion in cash in success-based milestone payments
  • Intellia Therapeutics in its multi-year collaboration with Regeneron on CRISPR/Cas gene-editing technology for in vivo therapeutic development, with $75 million upfront and potential milestone and royalty payments
  • Padlock Therapeutics in its sale to Bristol-Myers Squibb, valued up to $600 million with up-front and near-term payments of $225 million
  • Blueprint Medicines in its collaboration with Roche, up to $1 billion in value with $45 million upfront
  • Surface Oncology in its collaboration with Novartis to develop next generation immunotherapeutics, with Surface to receive up to $170 million in near term cash, plus milestones and royalties
  • Promedior in its option agreement with Bristol-Myers Squibb with potential deal value of up to $1.25 billion
  • Unum Therapeutics in its strategic collaboration with Seattle Genetics to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer, with potential deal value of $615 million
  • Foundation Medicine in its collaboration agreement and equity transaction with Roche, with total deal value in excess of $1 billion
  • F-star Alpha in its option agreement with Bristol-Myers Squibb with potential deal value up to $475 million
  • Teva Pharmaceuticals in its acquisition of Labrys Biologics, for $200 million cash and up to $825 million
  • Nogra Pharma in its $710 million global license agreement with Celgene for therapies to treat Crohn’s disease with a total potential deal value up to $2.6 billion in milestones, plus royalties
  • Alnylam Pharmaceuticals in its transformational alliance with Genzyme for RNAi therapeutics as genetic medicines along with a $700 million equity investment
  • bluebird bio in its global collaboration with Celgene and subsequent update for gene therapies to treat cancer with deal value up to $300 million
Public Offerings
  • Ra Pharmaceuticals in its $105 million initial public offering
  • Dimension Therapeutics in its $72 million initial public offering
  • aTyr Pharma in its $75 million initial public offering and earlier $76 million Series E financing
  • Blueprint Medicines in its $147 million initial public offering and $134.5 follow-on offering
  • Foundation Medicine in its $106 million initial public offering
  • Fate Therapeutics in its $40 million IPO, $30 million follow-on offering, and $57 million structured PIPE
Venture Financings
  • Arrakis Therapeutics in its $38 million financing to discover a new class of medicines directly targeting RNA
  • The neuroscience company Cerevance in its $36 million funding and spin-out from Takeda Pharmaceutical
  • Corvidia Therapeutics in its $26 million financing and in-license of a clinical stage asset from AstraZeneca
  • Pronutria Biosciences in its $81.5 million financings for amino acid-based products
  • Scholar Rock in its $56 million financings for therapeutics that target specific growth factors
  • Unum Therapeutics in its $65 million financing for its anti-body directed cellular immunotherapies
  • Semma Therapeutics in its $44 million financing for stem cell therapies for Type 1 diabetes
  • Surface Oncology in its $35 million financing for cancer immunotherapies
  • Aerpio Therapeutics in its $60 million financings for vascular disease therapies
  • SetPoint Medical in its $70 million financings for its implantable neuromodulation devices


Mr. Taft has been recognized by numerous legal guides for legal and life sciences industry expertise. In addition to the two listings noted above, Mr. Taft has also been named as a leading business lawyer by U.S. News-Best Lawyers (Biotechnology Law), LMG Life Sciences (Life Sciences Star), The Legal 500 United States (Healthcare: Life Sciences and Venture Capital and Emerging Companies), PLC Cross-border Life Sciences Handbook (Commercial and Partnering), IAM Patent 1000 (Licensing) and The International Who’s Who of Life Sciences Lawyers(Transactional).

Under his leadership, Goodwin’s Life Sciences Practice has received numerous awards and honors, including U.S. News’ Biotechnology Law Firm of the Year for four out of the last five years (2013 through 2015, and 2017), LMG Life Sciences’ Venture Capital Law Firm of the Year (2016), and perennial nationwide recognition by Chambers USA.

In The News

In den Nachrichten






J.D., 1997
Harvard Law School

(magna cum laude)

Ph.D., Chemistry, 1993
Massachusetts Institute of Technology
B.S., Chemistry, 1989
Yale University

(magna cum laude)


1997 to 1998 U.S. Court of Appeals for the Federal Circuit, Honorable Raymond C. Clevenger



Get In Touch
In Kontakt kommen
Get In Touch
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.
Search Other Lawyers
Suche Andere Rechtsanwälte